Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 10, Issue 2, Pages 173-178Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2009.12.002
Keywords
-
Categories
Ask authors/readers for more resources
Epoxyeicosatrienoic acids (EETs) build a family consisting of four arachidonic acid derived regioisomers that are generated by P450 epoxygenases. In the past years, growing interest in influencing EET level arose since EETs possess numerous beneficial effects in the cardiovascular system, for example, vasodilation, anti-inflammation and elicit renal and myocardial protection. Because EETs are primarily metabolized by the soluble epoxide hydrolase (sEH) and potent inhibitors of this enzyme are currently available, pharmacological sEH inhibition seems to be a feasible approach to elevate EET level in vivo. Hence, first clinical trials on sEH inhibition in man have begun. This review focuses on sEH inhibition as a novel pharmacological cardiovascular protective strategy with special regard to in vivo investigations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available